C57BL/6NCrl-Tg(DBH-Adra2a)#/Oulu
| Status | Available to order |
| EMMA ID | EM:10786 |
| Citation information | RRID:IMSR_EM:10786 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | C57BL/6NCrl-Tg(DBH-Adra2a)#/Oulu |
| Alternative name | hDBH-ADRA2A-Tg |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(DBH-Adra2a)# |
| Gene/Transgene symbol | Tg(DBH-Adra2a)# |
Information from provider
| Provider | Mika Scheinin |
| Provider affiliation | Pharmacology, Drug Development and Therapeutics, University of Turku |
| Genetic information | ADRA2A overexpression driven by human dopamine beta-hydroxylase (DBH) promoter (1.5 kbp long) |
| Phenotypic information | Homozygous:Not characterizedHeterozygous:Not characterized yet. The purpose of this line is to be backcrossed to global ADRA2A deficient mice in order to study the role of prejunctional ADRA2A receptors. Others have created a DBH-ADRA2A mouse crossed with ADRA2AC knock-out mouse (Gilsbach et al., 2009), but they used a 5.8 kbp DBH promoter sequence, which appears to give ectopic expression to cells with no endogenous DBH expression (Hoyle GW et al., 1994). We chose to use a more restricted sequence of the DBH promoter, which has been shown to target DBH-positive cells more specifically (Hoyle et al, 1994). |
| Breeding history | Heterozygous transgenic males are always mated with wildtype C57BL/6NCrl females. At the moment, we are in generation number 11. |
| References | None available |
| Homozygous fertile | not known |
| Homozygous viable | not known |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | University of Oulu, Oulu, Finland |
| Animals used for archiving | heterozygous C57BL/6NCrl males |